Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
Scientists are developing new treatment option for lung fibrosis

Scientists are developing new treatment option for lung fibrosis

Optibrium Enters Cheminformatics Collaboration with MSD

Optibrium Enters Cheminformatics Collaboration with MSD

Compound found in brown seaweeds could help treat malignant brain tumour

Compound found in brown seaweeds could help treat malignant brain tumour

Insilico signs multi-target drug discovery agreement with Janssen Pharmaceutica

Insilico signs multi-target drug discovery agreement with Janssen Pharmaceutica

New strategy shows promises for treating RNA-repeat expansion disorders

New strategy shows promises for treating RNA-repeat expansion disorders

UH professor is developing a Chinese herbal medicine formula to improve cancer therapy

UH professor is developing a Chinese herbal medicine formula to improve cancer therapy

REGENHU launches its next generation 3D Bioprinter and software, the R-GEN series and SHAPER, in its mission to revolutionize medicine

REGENHU launches its next generation 3D Bioprinter and software, the R-GEN series and SHAPER, in its mission to revolutionize medicine

Johns Hopkins researchers design tiny, star-shaped microdevices to deliver drugs

Johns Hopkins researchers design tiny, star-shaped microdevices to deliver drugs

Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development

Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development

Researchers develop new, improved human-skin equivalent

Researchers develop new, improved human-skin equivalent

Research projects receive BTCA grants to develop novel drugs for various diseases

Research projects receive BTCA grants to develop novel drugs for various diseases

Time machine suggests a drug testing approach for pancreatic cancer

Time machine suggests a drug testing approach for pancreatic cancer

Research program aims to thwart prion-like spread of tau pathology in Alzheimer’s disease

Research program aims to thwart prion-like spread of tau pathology in Alzheimer’s disease

Deep learning models help hunt for COVID-19 drugs

Deep learning models help hunt for COVID-19 drugs

CN Bio announces launch of drug metabolism and safety toxicity testing services

CN Bio announces launch of drug metabolism and safety toxicity testing services

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Advancements in research on cancer signal transduction and treatment

Advancements in research on cancer signal transduction and treatment

Cleveland Clinic-led study identifies features associated with pathogenic and benign variants

Cleveland Clinic-led study identifies features associated with pathogenic and benign variants

Novel machine learning algorithm helps find drug binding sites

Novel machine learning algorithm helps find drug binding sites

New peptide derivatives that target the SARS-CoV-2 spike protein

New peptide derivatives that target the SARS-CoV-2 spike protein

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.